[
  {
    "ts": null,
    "headline": "Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders",
    "summary": "MRNA shares jumped 5.3% as investors rotated into large-cap biotech, betting on its expanding pipeline in volatile trade.",
    "url": "https://finnhub.io/api/news?id=719bb6506d64f0852280f3e2295a7c91bd1cce868de7c3d430569bd08f02d3c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771246080,
      "headline": "Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders",
      "id": 139114276,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "MRNA shares jumped 5.3% as investors rotated into large-cap biotech, betting on its expanding pipeline in volatile trade.",
      "url": "https://finnhub.io/api/news?id=719bb6506d64f0852280f3e2295a7c91bd1cce868de7c3d430569bd08f02d3c8"
    }
  },
  {
    "ts": null,
    "headline": "3 Cash-Burning Stocks That Fall Short",
    "summary": "Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even bankruptcy.",
    "url": "https://finnhub.io/api/news?id=eca6b13d2aeb49316882fcda19ecad67843a34b88f8de1d2bc2c528434f36ca4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771217240,
      "headline": "3 Cash-Burning Stocks That Fall Short",
      "id": 139115969,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses risk dilution, mounting debt, or even bankruptcy.",
      "url": "https://finnhub.io/api/news?id=eca6b13d2aeb49316882fcda19ecad67843a34b88f8de1d2bc2c528434f36ca4"
    }
  },
  {
    "ts": null,
    "headline": "FDA Flu Setback Tests Moderna’s mRNA Pipeline And Regulatory Assumptions",
    "summary": "FDA issues a surprise refusal to review Moderna's mRNA-based flu vaccine filing, despite earlier agreement on trial design. Decision is described as unprecedented, with no cited safety or efficacy concerns in the application. The vaccine is under review in Europe, Canada, and Australia, while the US process stalls. Moderna, listed as NasdaqGS:MRNA, is best known for its mRNA based Covid 19 vaccine and has been working to extend that platform into seasonal flu and other respiratory diseases...",
    "url": "https://finnhub.io/api/news?id=aedf68c2285faee909d9e3dd02aa5effeb54b00d66a983addd4846874f13cc5d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771201205,
      "headline": "FDA Flu Setback Tests Moderna’s mRNA Pipeline And Regulatory Assumptions",
      "id": 139109381,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "FDA issues a surprise refusal to review Moderna's mRNA-based flu vaccine filing, despite earlier agreement on trial design. Decision is described as unprecedented, with no cited safety or efficacy concerns in the application. The vaccine is under review in Europe, Canada, and Australia, while the US process stalls. Moderna, listed as NasdaqGS:MRNA, is best known for its mRNA based Covid 19 vaccine and has been working to extend that platform into seasonal flu and other respiratory diseases...",
      "url": "https://finnhub.io/api/news?id=aedf68c2285faee909d9e3dd02aa5effeb54b00d66a983addd4846874f13cc5d"
    }
  }
]